CHINARES PHARMA Subsidiary Tasly Pharmaceutical Delivers 5.35% Revenue and 9.78% Profit Growth in Q1 2026

Bulletin Express04-24

China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three months ended 31 March 2026.

Key Operating Metrics • Revenue reached RMB 2.16 billion, up 5.35% from RMB 2.05 billion a year earlier, reflecting continued sales momentum. • Net profit rose to RMB 0.36 billion, a year-on-year increase of 9.78%, outpacing revenue growth and indicating improved operating leverage.

Balance-Sheet Snapshot (as at 31 March 2026) • Total assets: RMB 15.69 billion, up 2.30% from end-2025. • Total liabilities: RMB 2.79 billion, essentially unchanged from end-2025. • Owner’s equity: RMB 12.91 billion, expanding by 2.85% in three months, driven mainly by retained earnings.

Cash Flow • Net cash outflow for the quarter widened to RMB 0.82 billion, versus RMB 0.08 billion in the prior-year period. • Cash and cash equivalents stood at RMB 0.60 billion at quarter-end, down from RMB 0.74 billion a year earlier.

Compliance Note The figures are prepared under PRC GAAP and remain unaudited. They pertain solely to Tasly Pharmaceutical and do not represent the consolidated performance of CHINARES PHARMA. Shareholders and potential investors are advised to exercise caution when interpreting these results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147683141?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147683141","market":"us","top_or_hot":-1,"title":"CHINARES PHARMA Subsidiary Tasly Pharmaceutical Delivers 5.35% Revenue and 9.78% Profit Growth in Q1 2026","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three months ended 31 March 2026.</p>\n<p>Key Operating Metrics  \n• Revenue reached RMB 2.16 billion, up 5.35% from RMB 2.05 billion a year earlier, reflecting continued sales momentum.  \n• Net profit rose to RMB 0.36 billion, a year-on-year increase of 9.78%, outpacing revenue growth and indicating improved operating leverage.</p>\n<p>Balance-Sheet Snapshot (as at 31 March 2026)  \n• Total assets: RMB 15.69 billion, up 2.30% from end-2025.  \n• Total liabilities: RMB 2.79 billion, essentially unchanged from end-2025.  \n• Owner’s equity: RMB 12.91 billion, expanding by 2.85% in three months, driven mainly by retained earnings.</p>\n<p>Cash Flow  \n• Net cash outflow for the quarter widened to RMB 0.82 billion, versus RMB 0.08 billion in the prior-year period.  \n• Cash and cash equivalents stood at RMB 0.60 billion at quarter-end, down from RMB 0.74 billion a year earlier.</p>\n<p>Compliance Note  \nThe figures are prepared under PRC GAAP and remain unaudited. They pertain solely to Tasly Pharmaceutical and do not represent the consolidated performance of CHINARES PHARMA. Shareholders and potential investors are advised to exercise caution when interpreting these results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA Subsidiary Tasly Pharmaceutical Delivers 5.35% Revenue and 9.78% Profit Growth in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA Subsidiary Tasly Pharmaceutical Delivers 5.35% Revenue and 9.78% Profit Growth in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three months ended 31 March 2026.</p>\n<p>Key Operating Metrics  \n• Revenue reached RMB 2.16 billion, up 5.35% from RMB 2.05 billion a year earlier, reflecting continued sales momentum.  \n• Net profit rose to RMB 0.36 billion, a year-on-year increase of 9.78%, outpacing revenue growth and indicating improved operating leverage.</p>\n<p>Balance-Sheet Snapshot (as at 31 March 2026)  \n• Total assets: RMB 15.69 billion, up 2.30% from end-2025.  \n• Total liabilities: RMB 2.79 billion, essentially unchanged from end-2025.  \n• Owner’s equity: RMB 12.91 billion, expanding by 2.85% in three months, driven mainly by retained earnings.</p>\n<p>Cash Flow  \n• Net cash outflow for the quarter widened to RMB 0.82 billion, versus RMB 0.08 billion in the prior-year period.  \n• Cash and cash equivalents stood at RMB 0.60 billion at quarter-end, down from RMB 0.74 billion a year earlier.</p>\n<p>Compliance Note  \nThe figures are prepared under PRC GAAP and remain unaudited. They pertain solely to Tasly Pharmaceutical and do not represent the consolidated performance of CHINARES PHARMA. Shareholders and potential investors are advised to exercise caution when interpreting these results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1147683141","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147683141","pubTimestamp":1777023957,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"CHINARES PHARMA子公司天士力药业2026年第一季度收入增长5.35%，利润增长9.78%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three months ended 31 March 2026.\nKey Operating Metrics  \n• Revenue reached RMB 2.16 billion, up 5.35% from RMB 2.05 billion a year earlier, reflecting continued sales momentum.  \n• Net profit rose to RMB 0.36 billion, a year-on-year increase of 9.78%, outpacing revenue growth and indicating improved operating leverage.\nBalance-Sheet Snapshot (as at 31 March 2026)  \n• Total assets: RMB 15.69 billion, up 2.30% from end-2025.  \n• Total liabilities: RMB 2.79 billion, essentially unchanged from end-2025.  \n• Owner’s equity: RMB 12.91 billion, expanding by 2.85% in three months, driven mainly by retained earnings.\nCash Flow  \n• Net cash outflow for the quarter widened to RMB 0.82 billion, versus RMB 0.08 billion in the prior-year period.  \n• Cash and cash equivalents stood at RMB 0.60 billion at quarter-end, down from RMB 0.74 billion a year earlier.\nCompliance Note  \nThe figures are prepared under PRC GAAP and remain unaudited. They pertain solely to Tasly Pharmaceutical and do not represent the consolidated performance of CHINARES PHARMA. Shareholders and potential investors are advised to exercise caution when interpreting these results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147683141","isCrawlerRequest":true}